Biogen Inc. $BIIB Stock Purchased by Profund Advisors LLC

Profund Advisors LLC boosted its stake in Biogen Inc. (NASDAQ:BIIB) by 38.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,876 shares of the biotechnology company’s stock after acquiring an additional 3,316 shares during the period. Profund Advisors LLC’s holdings in Biogen were worth $2,683,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of BIIB. BlackRock Inc. purchased a new stake in Biogen in the 2nd quarter valued at $3,453,878,000. Primecap Management Co. CA purchased a new position in Biogen during the 2nd quarter worth $3,274,304,000. Wellington Management Group LLP grew its position in Biogen by 5.3% during the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after purchasing an additional 155,828 shares during the last quarter. Amundi increased its stake in Biogen by 91.8% in the second quarter. Amundi now owns 1,516,831 shares of the biotechnology company’s stock valued at $327,727,000 after purchasing an additional 726,004 shares during the period. Finally, Legal & General Group Plc acquired a new position in Biogen in the second quarter valued at $322,640,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on BIIB. Wall Street Zen upgraded Biogen from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Canaccord Genuity Group upped their price objective on Biogen from $248.00 to $272.00 and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley increased their price objective on Biogen from $231.00 to $238.00 and gave the stock an “equal weight” rating in a research report on Thursday. Wedbush lifted their target price on Biogen from $212.00 to $225.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. raised Biogen from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $210.00 to $300.00 in a report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and an average price target of $251.00.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $253.62 on Monday. Biogen Inc. has a fifty-two week low of $146.52 and a fifty-two week high of $258.78. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39. The firm’s 50-day simple moving average is $227.08 and its 200-day simple moving average is $201.04. The company has a market cap of $37.49 billion, a price-to-earnings ratio of 108.38, a PEG ratio of 2.88 and a beta of 0.10.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.63 billion. During the same period in the previous year, the business earned $4.81 earnings per share. Biogen’s quarterly revenue was up 10.6% compared to the same quarter last year. As a group, equities research analysts predict that Biogen Inc. will post 12.44 earnings per share for the current year.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.